Unlisted Shares
S3V Vascular Technologies Limited
S3V Vascular Technologies Limited (Unlisted)
Verified Unlisted CompanyOff-market Transfer · NSDL / CDSL
About S3V Vascular Technologies Limited
S3V Vascular Technologies Limited is a medical devices company focused on the manufacturing of vascular products used in cardiology and interventional procedures. The company develops specialized products catering to hospitals and healthcare providers, with a focus on innovation in minimally invasive treatments.
Share Details
| company Name | S3V Vascular Technologies Limited (Unlisted) |
| indicative Unlisted Share Price | ₹438 |
| market Capitalization | ₹632 Crore |
| lot Size | 500 |
| 52 Week High | ₹465 |
| 52 Week Low | ₹350 |
| face Value | ₹10 |
| book Value | 111.24 |
| pe Ratio | 116.25 |
| pb Ratio | 4.18 |
| debt To Equity | 0.13 |
| return On Equity | 0.04 |
| total Outstanding Shares | 13589284 |
| isin | INE0HCT01012 |
| depository | NSDL & CDSL |
| pan | AAQCS2303F |
| cin | U33112KA2011PLC059515 |
| rta | Aarthi Consultants |
Income Statement (Profit & Loss) (₹ in Crore)
| Particulars | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 21 | 19 | 15 | 13.5 |
| EBITDA | 5.8 | 3.7 | 2.5 | -0.57 |
| PBT | 2.8 | 0.65 | -3.06 | 0.15 |
| Net Profit / Loss (PAT) | 2.7 | 0.56 | -3.19 | 0.06 |
| EPS | 2.08 | 0.42 | -1.66 | 0.03 |
Key Financial Ratios (Last 3–5 Years)
| Ratio | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Operating Profit Margin (%) | 27.62 | 19.47 | 16.67 | -4.22 |
| Net Profit Margin (%) | 12.86 | 2.95 | -21.27 | 0.44 |
| Earning Per Share (Diluted) | 2.08 | 0.42 | -1.66 | 0.03 |
Financial Annual Report Summary
The company has experienced declining revenues and profitability over recent years. Margins have deteriorated significantly, with losses reported at operating and net levels in FY24 and weak recovery in FY25.
Why Invest in S3V Vascular Technologies
- Declining revenue trend over the last 3 years.
- Negative profitability in FY24 with weak recovery in FY25.
- Very low ROE indicates poor capital efficiency.
- High valuation despite weak financial performance.
Balance Sheet - Assets (₹ in Crore)
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Fixed Assets | 18.7 | 20 | 26 | 53.5 |
| CWIP | 2.4 | 2.8 | 6.6 | 15.6 |
| Investments | 0 | 0 | 0 | 0 |
| Trade Receivables | 31.6 | 34 | 37 | 42 |
| Inventory | 5.8 | 7 | 13 | 19 |
| Other Assets | 5.7 | 16.2 | 95.4 | 39.9 |
| Total Assets | 64 | 80 | 178 | 170 |
Balance Sheet - Liabilities & Equity (₹ in Crore)
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Share Capital | 13.01 | 13.21 | 191.7 | 191.7 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 22 | 26 | 122 | 122 |
| Borrowings | 20 | 30 | 25 | 18 |
| Trade Payables | 3 | 4 | 4.3 | 5.7 |
| Other Liabilities | 5.99 | 6.79 | 7.53 | 5.13 |
| Total Liabilities | 64 | 80 | 178 | 170 |
Liabilities Breakdown & Balance Sheet Insights
Balance Sheet Insights
Sharp increase in equity capital and assets in FY24 suggests capital infusion, but operational performance remains weak.
Liabilities Breakdown
Debt to Equity ratio of 0.13 indicates low leverage.
Additional Insights
Despite strong equity infusion, profitability and efficiency remain concerns.
Cash Flow Insights
- Negative operating cash flow indicates weak core operations.
- Heavy investment outflows continue.
- FY24 saw strong financing inflow due to capital raise.
Shareholding Pattern
Recent
Promoter: High
Institutional: Low
Public: Low
Promoters & Management
Promoter-driven medical device company focusing on vascular technologies.
Key Management
Not Available
Registrar & Transfer Agent (RTA)
Registrar: Aarthi Consultants
Management Analysis
Focused on scaling vascular product portfolio, but currently facing operational and financial challenges.
Frequently Asked Questions About S3V Vascular Technologies Limited
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.